Evidence map›Paper›PMID 31733070›Full record

ArticleJournal of surgical oncology2019

Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma.

Apostolos Gaitanidis, Douglas Wiseman, Mustapha El Lakis, Naris Nilubol, Electron Kebebew, Dhaval Patel

Open access · greenAbstract read
In one paragraph

Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Serum Inflammation-based Scores in Endocrine Tumors.The Journal of clinical endocrinology and metabolism · 2021
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Apostolos GaitanidisSurgical Oncology Program, National Cancer Institute, Bethesda, Maryland.ORCID http://orcid.org/0000-0003-3045-5252
Douglas WisemanSurgical Oncology Program, National Cancer Institute, Bethesda, Maryland.
Mustapha El LakisDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Naris NilubolSurgical Oncology Program, National Cancer Institute, Bethesda, Maryland.
Electron KebebewDepartment of Surgery, Stanford University School of Medicine, Stanford, California.
Dhaval PatelSurgical Oncology Program, National Cancer Institute, Bethesda, Maryland.
National Cancer Institute · USDemocritus University of Thrace · GRMedical College of Wisconsin · USStanford University · USUniversity of Pittsburgh · US

Funding

Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Center for Cancer Research, National Cancer Institute, National Institutes of HealthIntramural NIH HHS ZIA BC011286NIH Clinical Center
6 · The paper itself

Abstract

backgroundRecurrent adrenocortical carcinoma (ACC) has a poor prognosis with minimal clinical and biochemical factors to guide management. The aim of this study was to evaluate the prognostic significance of systemic inflammatory response in patients with recurrent ACC.

methodsPatients who underwent resection for recurrent ACC were retrospectively analyzed. Preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), and mean platelet volume were calculated.

resultsTwenty-five patients (age at operation 52.2 ± 9.5 years) were identified. We observed a statistically significant shorter disease-specific survival (DSS) in patients with LMR less than 4 (41 ± 7.4 months vs 71 ± 12.3, P = .023) and male sex (26.6 ± 4.2 months vs 57.6 ± 9.5 months, P = .079), while time-to-recurrence (TTR) less than 12 months (40 ± 7.7 months vs 70.3 ± 13.1 months, P = .059) had a trend on univariate analysis for worse DSS. On multivariable analysis, LMR < 4 (hazard ratio [HR] 4.18; 95% confidence interval [CI]: 1.18-14.76; P = .027) and TTR less than 12 months (HR 2.77 95% CI: 1-7.62; P = .049) were found to be significantly associated with worse DSS.

conclusionPreoperative LMR greater than 4 and TTR greater than 12 months are associated with longer DSS. Patients with LMR greater than 4 and TTR greater than 12 months may benefit from a more aggressive therapeutic approach and may require less frequent surveillance.

Indexed as

Lymphocyte CountAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultBiomarkersCell CountFemaleHumansMaleMiddle AgedMonocytesNeoplasm Recurrence, LocalPreoperative PeriodPrognosisRetrospective StudiesTime FactorsBiomarkersadrenocortical cancerlymphocytemonocyterecurrence

Identifiers

PMID31733070
PMCPMC8192065
OpenAlexW2988230642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.